Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2017 | Pages:
72 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Otitis Media - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Otitis Media - Pipeline Review, H2 2017, provides an overview of the Otitis Media (Ear Nose Throat Disorders) pipeline landscape. Otitis media (OM) is any inflammation of the middle ear, the air-filled space behind the eardrum that contains the tiny vibrating bones of the ear. Symptoms include ear pain, difficulty sleeping, loss of balance, fever, headache and loss of appetite. Risk factors include age, seasonal factors and exposure to tobacco smoke or high levels of air pollution. Treatment includes antibiotics and antipyrine. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Otitis Media - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Otitis Media (Ear Nose Throat Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Otitis Media (Ear Nose Throat Disorders) pipeline guide also reviews of key players involved in therapeutic development for Otitis Media and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 2, 3 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively. Otitis Media (Ear Nose Throat Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Otitis Media (Ear Nose Throat Disorders). - The pipeline guide reviews pipeline therapeutics for Otitis Media (Ear Nose Throat Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Otitis Media (Ear Nose Throat Disorders) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Otitis Media (Ear Nose Throat Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Otitis Media (Ear Nose Throat Disorders) Reasons to buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Otitis Media (Ear Nose Throat Disorders). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Otitis Media (Ear Nose Throat Disorders) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Otitis Media - Overview Otitis Media - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Otitis Media - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Otitis Media - Companies Involved in Therapeutics Development ContraFect Corp GlaxoSmithKline Plc Lee's Pharmaceutical Holdings Ltd Madam Therapeutics BV Merck & Co Inc MerLion Pharmaceuticals Pte Ltd Novus Therapeutics Inc Otonomy Inc Yuhan Corp Otitis Media - Drug Profiles (cholesteryl palmitate + colfosceril palmitate) - Drug Profile Product Description Mechanism Of Action R&D Progress (dexamethasone acetate + piperacillin sodium + tazobactam sodium) - Drug Profile Product Description Mechanism Of Action R&D Progress betahistine dihydrochloride - Drug Profile Product Description Mechanism Of Action R&D Progress CF-303 - Drug Profile Product Description Mechanism Of Action R&D Progress CF-309 - Drug Profile Product Description Mechanism Of Action R&D Progress ciprofloxacin hydrochloride - Drug Profile Product Description Mechanism Of Action R&D Progress finafloxacin - Drug Profile Product Description Mechanism Of Action R&D Progress GSK-2189242A - Drug Profile Product Description Mechanism Of Action R&D Progress pazufloxacin - Drug Profile Product Description Mechanism Of Action R&D Progress PCL-1440 - Drug Profile Product Description Mechanism Of Action R&D Progress pneumococcal (23-valent) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress Recombinant Peptide to Inhibit DNA for Otitis Media and Haemophilus Influenzae Infections - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules for Otitis Media - Drug Profile Product Description Mechanism Of Action R&D Progress solithromycin - Drug Profile Product Description Mechanism Of Action R&D Progress Otitis Media - Dormant Projects Otitis Media - Product Development Milestones Featured News & Press Releases Jun 22, 2017: Otonomy Announces Successful End-of-Phase 2 Review by FDA for OTIPRIO in Acute Otitis Media with Tympanostomy Tubes Jun 02, 2017: Eight Presentations at ASM Microbe Include Late Breaker From Cempra's Phase 3 Fusidic Acid Study and Solithromycin Data on Gonorrhea and Otitis Media May 12, 2017: Otonomy Announces OTIPRIO Data Presentation and Symposium at the American Society of Pediatric Otolaryngology Annual Meeting Nov 02, 2016: Otonomy Announces Assignment of J Code for OTIPRIO Oct 07, 2016: Otonomy Holds Investor and Analyst Day and Provides Corporate Update Oct 04, 2016: Otonomy Successfully Completes Phase 2 Clinical Trial of OTIPRIO in Pediatric Patients with Acute Otitis Media with Tympanostomy Tubes Sep 15, 2016: Otonomy Successfully Completes Open-Label Clinical Trial for OTIPRIO in Patients with History of Otitis Media Requiring Tympanostomy Tubes May 20, 2016: Otonomy Announces Assignment of C Code and Pass-Through Payment Status for OTIPRIO May 16, 2016: Otonomy Announces OTIPRIO Data Presentation and Symposium at Combined Otolaryngology Spring Meetings Mar 18, 2016: Otonomy Announces Publication of OTIPRIO Phase 3 Clinical Trial Results in JAMA Otolaryngology Mar 03, 2016: Otonomy Initiates Phase 2 Clinical Trial of OTIPRIO in Pediatric Patients With Acute Otitis Media With Tympanostomy Tubes Mar 02, 2016: Otonomy Announces Commercial Availability of OTIPRIO Dec 11, 2015: Otonomy Announces FDA Approval of OTIPRIO for the Treatment of Pediatric Patients Undergoing Tympanostomy Tube Placement Surgery Nov 03, 2015: Otonomy Initiates Open-Label Clinical Trial for OTIPRIO in Pediatric Patients With History of Otitis Media Requiring Tympanostomy Tubes Sep 24, 2015: Otonomy to Present Results for AuriPro Phase 3 Clinical Trials at 2015 AAO-HNSF Annual Meeting Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for Otitis Media, H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products under Development by Universities/Institutes, H2 2017 Products under Development by Companies, H2 2017 Products under Development by Universities/Institutes, H2 2017 Number of Products by Stage and Target, H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Otitis Media - Pipeline by ContraFect Corp, H2 2017 Otitis Media - Pipeline by GlaxoSmithKline Plc, H2 2017 Otitis Media - Pipeline by Lee's Pharmaceutical Holdings Ltd, H2 2017 Otitis Media - Pipeline by Madam Therapeutics BV, H2 2017 Otitis Media - Pipeline by Merck & Co Inc, H2 2017 Otitis Media - Pipeline by MerLion Pharmaceuticals Pte Ltd, H2 2017 Otitis Media - Pipeline by Novus Therapeutics Inc, H2 2017 Otitis Media - Pipeline by Otonomy Inc, H2 2017 Otitis Media - Pipeline by Yuhan Corp, H2 2017 Otitis Media - Dormant Projects, H2 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
